A digital approach to the care of patients with heart failure, developed by Boehringer Ingelheim and ORCHA, will be rolled out in the northwest of the UK by a primary care
AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
Dutch-Swiss start-up Cradle has raised €22 million ($24 million) in first-round financing to develop its generative artificial intelligence (GenAI) and synthetic biology p
In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibody discovery
EVERSANA’s alliance with Amazon Web Services (AWS) on the application of generative artificial intelligence (GenAI) to the pharma sector has borne its first fruit – a new